摘要
目的探讨左旋甲状腺激素对妊娠合并亚临床甲状腺功能减退症(SCH)孕产妇妊娠结局及围产儿结局的影响。方法选取医院2014年2月至2016年12月产科就诊收治的妊娠合并SCH患者80例,随机分为治疗组和对照组,各40例。治疗组给予左旋甲状腺激素(L-T4)治疗。并同期选取甲状腺功能的健康孕妇40例作为健康对照组。比较并分析所有研究对象妊娠结局及围产儿结局,包括流产、早产、新生儿死亡、胎窘、胎膜早破、妊娠贫血、妊娠期糖尿病、先兆子痫等情况。结果经L-T4治疗,治疗组、健康对照组的新生儿早产率、新生儿死亡率、自然流产率、胎膜早破发生率、胎窘发生率、妊娠孕产妇贫血率、妊娠期孕产妇糖尿病发生率、先兆子痫发生率均明显低于对照组(P<0.05),治疗组和健康对照组产妇妊娠结局及围产儿结局情况比较,差异无统计学意义(P>0.05),表明经L-T4治疗,治疗组产妇妊娠结局及围产儿结局情况均优于对照组。结论 T-T4治疗妊娠合并SCH孕产妇可降低其不良妊娠结局及不良围产儿结局的发生率,有效改善母儿预后。
Objective To investigate the effect of of Levothyroxine on pregnancy outcome and perinatal outcome in pregnant women with subclinical hypothyroidism（ SCH）. Methods Totally 80 pregnant women with SCH in our hospital from February 2014 to December 2016 were selected and divided into the treatment group and the contorl group according to whether or not to give Levothyroxine treatment,40 cases in each group. At the same time,40 healthy pregnant women were selected as the healthy control group. The pregnancy and perinatal outcomes including abortion, premature birth, perinatal death, fetal distress, premature rupture of membranes, anemia, gestational diabetes and preeclampsia were compared among the three groups. Results After treated by Levothyroxine, the rate of premature birth,neonatal mortality,spontaneous abortion and fetal distress,pregnancy,maternal anemia and maternal diabetes incidence,preeclampsia in the treatment group and the healthy control group were significantly lower than those in the contorl group, and the difference were statistically significant（ P〈0. 05）. There was no statistically significant difference about maternal pregnancy and perinatal outcomes between the treatment group and the control group（ P〉0. 05）, it showed that the outcome of pregnancy and perinatal outcomes of the treatment group after treated by Levothyroxine were better than those of the contorl group. Conclusion The application of Levothyroxine in pregnant women with SCH can reduce the incidence of adverse pregnancy outcomes and adverse perinatal outcomes,and improve the prognosis of mothers and infants.
作者
王永丽
Wang Yongli(Department of Obstetrics and Gynecology, Zhengzhou Yihe Hospital, Zhengzhou, Henan, China 45000)
出处
《中国药业》
CAS
2017年第11期67-69,共3页
China Pharmaceuticals
